Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
de Jong EJM, Janssen QP, Simons TFA, Besselink MG, Bonsing BA, Bouwense SAW, Geurts SME, Homs MYV, de Meijer VE, Tjan-Heijnen VCG, van Laarhoven HWM, Valkenburg-van Iersel LBJ, Wilmink JW, van der Geest LG, Koerkamp BG, de Vos-Geelen J; Dutch Pancreatic Cancer Group.
de Jong EJM, et al. Among authors: van laarhoven hwm, van der geest lg.
Int J Cancer. 2022 May 15;150(10):1654-1663. doi: 10.1002/ijc.33916. Epub 2021 Dec 31.
Int J Cancer. 2022.
PMID: 34935139
Free PMC article.